Is Achillion a Bad News Buy Post-Bloodbath?
This episode of The Motley Fool's Market Checkup drills down on the hottest headlines and biggest market movers in the health-care sector.
In this video, health-care analysts David Williamson and Max Macaluso discuss Achillion Pharmaceuticals' no good, very bad day. The company announced after the market closed on Friday that its hepatitis C drug sovaprevir would remain on clinical hold. Shares have been slashed in half by investors.
Achillion is in a tough position. It has a broad range of hep C drugs, but it is far back in development from its deep-pocketed competitors. Gilead and Johnson & Johnson have drugs under FDA review right now, while Gilead and AbbVie each plans to offer interferon free "drug cocktails" soon after. Combine that with a litany of safety-related clinical holds in next-gen hep-C treatments and investors hoping for a quick resolution for what looked to be a drug-to-drug related interaction are left disappointed.
David and Max take a closer look at how this delay impacts Achillion, why investors were even more skittish after the conference call, and if the stock's sell-off made it a bad news buy.
Three biotech buys
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article Is Achillion a Bad News Buy Post-Bloodbath? originally appeared on Fool.com.David Williamson owns shares of AbbVie and Johnson & Johnson. Follow David on Twitter @MotleyDavid.Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.